You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 152 No. 12, DECEMBER 1992 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL OBSERVATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (60)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Cryptosporidiosis With Paromomycin

A Report of Five Cases

Keith Armitage, MD; Timothy Flanigan, MD; John Carey, MD; Ian Frank, MD; Rob Roy MacGregor, MD; Paul Ross, MD; Richard Goodgame, MD; John Turner, MD

Arch Intern Med. 1992;152(12):2497-2499.


Abstract

Cryptosporidiosis continues to be one of the most devastating complications of the acquired immunodeficiency syndrome, causing severe, chronic diarrhea that is largely refractory to treatment. More than 60 drugs have been tried in the treatment of cryptosporidiosis, none of which have been consistently successful. We describe the successful treatment of cryptosporidiosis in five patients with acquired immunodeficiency syndrome with oral paromomycin at a dose of 1500 to 2000 mg/d. All five patients had resolution of symptoms and normalization of bowel movements, although one patient later relapsed while receiving paromomycin. Three of five patients cleared Cryptosporidium from the stool. Paromomycin is a promising therapy for cryptosporidiosis in acquired immunodeficiency syndrome and further prospective clinical trials are warranted.

(Arch Intern Med. 1992;152:2497-2499)



Author Affiliations

From the Department of Medicine, University Hospitals, Cleveland, Ohio (Dr Armitage); Department of Medicine, Miriam Hospital, Providence, RI (Dr Flanigan); Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia (Drs Frank and MacGregor); Department of Medicine, Baylor College of Medicine, Houston, Tex (Drs Ross and Goodgame; and the Department of Medicine, The Graduate Hospital, Philadelphia, Pa (Dr Turner).


Footnotes

Accepted for publication April 10, 1992.

Reprint requests to the Department of Medicine, Brown University, Miriam Hospital, 164 Summit Ave, Providence, Rl 02906 (Dr Flanigan).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Dicyclic and Tricyclic Diaminopyrimidine Derivatives as Potent Inhibitors of Cryptosporidium parvum Dihydrofolate Reductase: Structure-Activity and Structure-Selectivity Correlations
Nelson and Rosowsky
Antimicrob. Agents Chemother. 2001;45:3293-3303.
ABSTRACT | FULL TEXT  

Correction of the Hyper-IgM Syndrome after Liver and Bone Marrow Transplantation
Hadzic et al.
NEJM 2000;342:320-324.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1992 American Medical Association. All Rights Reserved.